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OBJECTIVE — Lactic acidosis has been associated with use of metformin. Hypoglycemia is a
major concern using sulfonylureas. The aim of this study was to compare the risk of lactic
acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs.
RESEARCH DESIGN AND METHODS — This study is a nested case-control analysis
usingtheU.K.-basedGeneralPracticeResearchDatabasetoidentifypatientswithtype2diabetes
who used oral antidiabetes drugs. Within the study population, all incident cases of lactic
acidosis and hypoglycemia were identiﬁed, and hypoglycemia case subjects were matched to up
to four control patients based on age, sex, practice, and calendar time.
RESULTS — Amongthestudypopulationof50,048type2diabeticsubjects,sixcasesoflactic
acidosis during current use of oral antidiabetes drugs were identiﬁed, yielding a crude incidence
rate of 3.3 cases per 100,000 person-years among metformin users and 4.8 cases per 100,000
person-years among users of sulfonylureas. Relevant comorbidities known as risk factors for
lactic acidosis could be identiﬁed in all case subjects. A total of 2,025 case subjects with hypo-
glycemia and 7,278 matched control subjects were identiﬁed. Use of sulfonylureas was associ-
ated with a materially elevated risk of hypoglycemia. The adjusted odds ratio for current use of
sulfonylureas was 2.79 (95% CI 2.23–3.50) compared with current metformin use.
CONCLUSIONS — Lactic acidosis during current use of oral antidiabetes drugs was very
rareandwasassociatedwithconcurrentcomorbidity.Hypoglycemicepisodesweresubstantially
more common among sulfonylurea users than among users of metformin.
Diabetes Care 31:2086–2091, 2008
M
etforminplaysapivotalroleinthe
treatment of patients with type 2
diabetes (1). Metformin decreases
basal glucose output by suppressing glu-
coneogenesis and glycogenolysis in liver
and increasing glucose disposal in muscle
tissue. As the most worrisome complica-
tion, lactic acidosis (pH 7.37 and/or
plasma lactate levels 4 mmol/l) contin-
ues to be discussed in the literature (2)
even though the absolute risk appears to
be low, with incidence rates of lactic ac-
idosis associated with metformin use
ranging from 1 to 16.7 cases per
100,000 patient-years (3,4). Salpeter et
al. (5) identiﬁed all trials and cohort
studies conducted between 1959 and
2002 and did not ﬁnd a single case of
lacticacidosisin36,893person-yearsof
metforminexposure.LalauandRace(6)
analyzed 49 cases of lactic acidosis as-
sociated with metformin use; overall
mortality was not correlated with
plasma lactate concentrations. Interest-
ingly,plasmametforminconcentrations
were, on average, three times higher in
patients who survived. All case subjects
with lactic acidosis had, in addition to
metformin use, acute or chronic comor-
bidities predisposing to lactic acidosis.
These data suggest that lactic acidosis
may be coincidental rather than caus-
ally associated with metformin use.
Metformin alone is not (7,8) or only
rarely (1) associated with hypoglycemia
(deﬁned as symptoms and signs of hypo-
glycemia and/or plasma glucose levels
3.3mmol/landclinicalresponsetoglu-
cose administration). According to a re-
cent review (9), the reported risks of
hypoglycemia for metformin users varied
between 0 and 21%. Since metformin
does not directly stimulate insulin secre-
tion, hypoglycemia risk may be lower
than for that of other oral antidiabetes
drugs. However, hypoglycemia in pa-
tients using metformin may occur in as-
sociation with strenuous physical activity
or fasting.
Hypoglycemia is a major concern for
users of sulfonylureas. Magnitude and se-
verity of sulfonylurea-induced hypogly-
cemia range widely across studies
(1,9,10). In an observational study (11),
the annual risk for a ﬁrst hypoglycemia
diagnosis associated with sulfonylurea
usewas1.8%(1,800per100,000person-
years); long-acting formulations, renal
impairment, older age, and incidental use
of sulfonylureas were associated with a
higher hypoglycemia risk. Despite many
reportsontheriskofhypoglycemiainpa-
tientsusingoralantidiabetesdrugs,direct
comparisons between drug classes in the
same study population are rare (9). Fur-
thermore, the deﬁnition of hypoglycemia
varies considerably across previous stud-
ies, and a comparison of their results is
therefore difﬁcult (7). Additionally, no
previous study quantiﬁed both the risk of
developing lactic acidosis and hypoglyce-
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formin in the same study population.
Therefore, we conducted an observa-
tional study to compare the risk of lactic
acidosis and hypoglycemia among users
of metformin, sulfonylureas, or other oral
antidiabetes drugs.
RESEARCH DESIGN AND
METHODS— Datawerederivedfrom
the U.K.-based General Practice Research
Database (GPRD) (12,13). Brieﬂy, this
database was established around 1987
and currently encompasses 5 million
people who are enrolled with selected
generalpractitioners(GPs),covering50
million person-years of follow-up. The
patients enrolled in the GPRD are repre-
sentative of the U.K. with regard to age,
sex, geographic distribution, and annual
turnover rate. GPs have been trained to
record medical information, including
demographic data, medical diagnoses,
hospitalizations, deaths, and drug pre-
scriptions, using standard software and
standard coding systems. The GPs gener-
ate prescriptions directly with the com-
puter; this information is automatically
transcribed into the computer record. It
contains the name of the preparation, in-
structions for use, route of administra-
tion, dose, and number of tablets for each
prescription. The recorded information
on drug exposure and diagnoses has been
validatedandproventobeofhighquality
(14,15). The GPRD has been the source
of many observational studies, including
research on diabetes and antidiabetes
drugs (11,16). The study was approved
by the Independent Scientiﬁc Advisory
Committee for Medicines and Healthcare
Products Regulatory Agency database
research.
We identiﬁed in the GPRD all sub-
jects who received at least one prescrip-
tion for a sulfonylurea (glibenclamide,
gliclazide, glipizide, glimepiride, glib-
ornuride, gliquidone, tolbutamide,
chlorpropamide, tolazamide, or aceto-
hexamide), a biguanide (metformin), a
thiazolidinedione (pioglitazone, rosiglita-
zone, or troglitazone), an -glucosidase
inhibitor(acarbose),oraprandialglucose
regulator (repaglinide or nateglinide),
with or without concomitant insulin use,
and who were between the ages of 30 and
79yearsbetween1994and2005.Wedid
not include type 1 diabetic subjects with
insulin-dependent diabetes who had
never used oral antidiabetes drugs. We
excluded all patients with 3 years of re-
corded history in the database before the
ﬁrstprescriptionforanantidiabetesdrug,
as well as all patients with alcoholism, a
history of cancer (except nonmelanoma
skincancer),andwomenwithadiagnosis
of gestational diabetes at any time in their
record.
Case deﬁnition and control selection
Withinthisdiabeticstudypopulation,we
identiﬁed all patients between age 30 and
89 years with a ﬁrst-time diagnosis of lac-
tic acidosis or hypoglycemia after the ﬁrst
prescriptionforanoralantidiabetesdrug.
The date of this ﬁrst diagnosis of interest
will be referred to as the index date. We
manuallyreviewedallcasesubjectswitha
recorded hypoglycemia diagnosis,
blinded to any exposure of interest, and
classiﬁed them into “mild to moderate” if
they were diagnosed and treated by the
GP or “severe” if they had to be hospital-
ized and/or died at the index date. We
sent for original medical records in the
U.K. for all potential lactic acidosis cases.
Within the study population, we identi-
ﬁed at random up to four control patients
per hypoglycemia case subject, matched
to case subjects with regard to age (same
year of birth), sex, general practice, and
index date (i.e., the date of the hypogly-
cemia diagnosis of the case).
Statistical analysis
We assessed from the computer records
exposure to oral antidiabetes drugs and
insulin before the index date in case and
control subjects. We classiﬁed users of
antidiabetes drugs according to the drug
class (insulin, sulfonylureas, metformin,
thiazolidinediones, prandial glucose reg-
ulators, or -glucosidase inhibitors), the
Table 1—Oral antidiabetes drug use in seven case subjects with lactic acidosis
Case
no.
Age
(years)/
sex
Use of oral antidiabetes
drugs
Approximate duration
of metformin use
prior to diagnosis
(months)
Time between last
metformin
prescription and
diagnosis (days)
Relevant comorbidities and outcome
(died or survived)
1 83/female Metformin, glibenclamide 57 21 Acute renal failure, acute heart failure
(hypertensive heart disease) (died)
2 63/female Metformin, gliclazide 11 13 Acute seizure, stable hypertensive
heart disease, nonexacerbated
chronic obstructive pulmonary
disease (survived)
3 70/female Gliclazide — — Urosepsis (survived)
4 74/male Metformin, gliclazide 11 106* Stable hypertensive heart disease,
nonexacerbated chronic
obstructive pulmonary disease
(survived)
5 82/female Metformin 29 52 Acute gastroenteritis with
hypovolemia (died)
6 42/female Metformin, pioglitazone 82 7 Stable hypertensive heart disease,
liver cirrhosis (survived)
7 70/male Metformin, gliclazide 32 36 Acute heart failure (hypertensive
heart disease) (survived)
*Patient no. 4 was classiﬁed as a “past metformin user” because the tablet supply of the last metformin prescription prior to the index date was likely to not last up
to or beyond the index date (for details, see text).
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prescription for a drug of interest was re-
corded 60 days; or past use, if it was
recorded 60 days before the index
date), and the duration of use, based on
thenumberofprescriptionsbeforethein-
dex date (none, 1–4, 5–14, or 15 pre-
scriptions). We assessed crude incidence
rates, in person-years, of the outcomes of
interest for current metformin and sulfo-
nylureause,basedonthenumberofusers
of these drugs in the study population,
their total number of recorded prescrip-
tions, and the average number of tablets
per prescription.
Weconductedconditionallogisticre-
gression analyses using SAS 9.1 (SAS In-
stitute, Cary, NC) to compare the
exposure prevalence between hypoglyce-
mic case subjects and control subjects.
Risk estimates are presented as odds ra-
tios with 95% CIs. P values are two-sided
and considered statistically signiﬁcant if
0.05. In one model, we compared met-
formin users with nonusers of metformin
and adjusted for use of sulfonylureas;
other oral antidiabetes drugs; insulin;
smoking status (none, current, past, or
unknown); BMI (25, 25–29.9, or 30
kg/m
2);avarietyofdiagnosedcomorbidi-
ties potentially associated with an altered
hypoglycemia risk such as renal failure,
diabetic neuropathy, diabetic retinopa-
thy, congestive heart failure, ischemic
heart disease, stroke/transient ischemic
attack, hypotension, hypertension, hy-
perlipidemia, depression, and/or suicidal
ideation; and the use of various antihy-
pertensives, diuretics, antiarrhythmic
drugs, lipid-lowering agents, inhaled or
systemic corticosteroids, stomach
acid–reducing drugs, analgesics, anti-
epileptic drugs, benzodiazepines, anti-
psychotics, or antidepressants. In a
second model, we compared users of sul-
fonylureaswithnonusersofsulfonylureas
and adjusted for metformin use and all
other variables displayed above. In a fur-
thermodel,wedirectlycomparedtherisk
ofdevelopinghypoglycemiabetweencur-
rent metformin users and current sulfo-
nylurea users and adjusted for use of
other antidiabetes agents.
RESULTS— Thestudypopulationen-
compassed 50,048 patients who received
at least one prescription for at least one
study drug. The mean  SD age of sub-
jects of the study population was 60.7 
11.7 years, and 54.8% were women.
Lactic acidosis
We identiﬁed 14 patients with a recorded
code for lactic acidosis. After manual re-
view of the medical records, we excluded
seven patients because they had ketoaci-
dosis, respiratory acidosis, or nonacidotic
hyperosmolar dysfunction. Five patients
were current metformin users, one pa-
tient (no. 4) was classiﬁed as a past met-
formin user, and one was a current
gliclazide user (Table 1). Among six case
Table 2—Characteristics and comorbidities of hypoglycemia case (n  2,025) and control (n  7,278) subjects
Parameter
Case
subjects Control subjects
Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)* P value
Age (years) —— —
50 262 (12.9) 747 (10.6)
50–59 356 (17.6) 1,304 (17.9) — — —
60–69 592 (29.2) 2,234 (30.7) — — —
70–79 649 (32.1) 2,384 (32.8) — — —
80 166 (8.2) 582 (8.0) — — —
Sex —— —
Male 969 (47.9) 3,523 (48.4)
Female 1,056 (52.2) 3,755 (51.6) — — —
Smoking
Nonsmoker 1,031 (50.9) 3,692 (50.7) 1.0 (reference) 1.0 (reference) —
Current smoker 297 (14.7) 1,257 (17.3) 0.84 (0.72–0.97) 0.75 (0.63–0.89) 0.001
Past smoker 607 (30.0) 1,950 (26.8) 1.17 (1.03–1.32) 1.04 (0.91–1.20) 0.58
Unknown 90 (4.4) 379 (5.2) 0.78 (0.59–1.02) 0.82 (0.59–1.14) 0.24
BMI (kg/m
2)
25.0 346 (17.1) 1,052 (14.5) 1.0 (ref.) 1.0 (ref.) —
25.0–29.9 712 (35.1) 2,527 (34.7) 0.87 (0.75–1.01) 0.87 (0.73–1.04) 0.13
30.0 840 (41.5) 3,179 (43.7) 0.81 (0.69–0.94) 0.68 (0.57–0.82) 0.0001
Unknown 127 (6.3) 520 (7.1) 0.74 (0.58–0.94) 0.78 (0.58–1.05) 0.10
Renal failure 157 (7.8) 339 (4.7) 1.76 (1.44–2.15) 1.58 (1.25–2.00) 0.001
Diabetic retinopathy 41 (2.0) 123 (1.7) 1.19 (0.82–1.71) 1.07 (0.70–1.62) 0.77
Diabetic neuropathy 57 (2.8) 120 (1.7) 1.91 (1.35–2.69) 1.25 (0.83–1.87) 0.29
Ischemic heart disease/congestive
heart failure 654 (32.3) 2,132 (29.3) 1.21 (1.08–1.36) 0.84 (0.72–0.98) 0.02
Stroke/transient ischemic attack 248 (12.3) 706 (9.7) 1.36 (1.16–1.59) 1.13 (0.93–1.36) 0.21
Hypotension 69 (3.4) 165 (2.3) 1.57 (1.16–2.11) 1.02 (0.72–1.44) 0.91
Hypertension 1,056 (52.2) 3,772 (51.8) 1.06 (0.95–1.17) 0.95 (0.82–1.10) 0.47
Hyperlipidemia 547 (28.4) 1,910 (26.2) 1.15 (1.02–1.29) 1.00 (0.87–1.14) 0.94
Depression/suicide ideas 545 (26.9) 1,468 (20.2) 1.46 (1.30–1.65) 1.13 (0.95–1.33) 0.17
Dataaren(%),unlessotherwiseindicated.*Adjustedforallthevariablesdisplayedinthetableplusforuseoforalantidiabetesdrugs,insulin,antihypertensivedrugs,
lipid-lowering agents, diuretics, inhaled and systemic corticosteroids, anticonvulsants, antidepressants, neuroleptics, benzodiazepines, stomach acid–reducing
drugs, and analgesics.
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betes drugs, ﬁve suffered from acute
worsening of known risk factors for lactic
acidosis, namely acute heart failure, uro-
sepsis,hypovolaemia,seizure,oracutere-
nal failure. Two of seven patients died
(nos. 1 and 5). Based on the number of
metformin users, prescriptions, and aver-
age number of tablets per metformin pre-
scription, we assessed a crude incidence
rateoflacticacidosisinmetfominusersof
3.3 per 100,000 person-years. The
crudeincidencerateoflacticacidosisdur-
ingcurrentuseofsulfonylureaswas4.8
per 100,000 person-years. Due to the
small case number, no formal analyses
were conducted.
Hypoglycemia
Within the study population, we identi-
ﬁed2,025casesubjectswithrecordedhy-
poglycemia and 7,278 matched control
subjects. Based on a manual computer
record review, we classiﬁed 73 of 2,025
(3.6%) as severe hypoglycemic episodes,
deﬁned as leading to an emergency hos-
pitalization and/or to death. Based on a
crude person-time assessment, the inci-
denceratesforcurrentusersofmetformin
orsulfonylureaswere60per100,000and
110 per 100,000 person-years, respec-
tively (Table 2). The odds ratio of devel-
oping hypoglycemia in association with
current metformin use was 1.42 (95% CI
1.22–1.64) and with current use of a sul-
fonylurea drug 3.73 (3.16–4.42), com-
pared with nonuse of the respective drug
classes and adjusted for each other, cur-
rent use of insulin, other oral antidiabetes
drugs, smoking, BMI, comorbidities, and
various comedication (Table 3).
To exclude the possibility of residual
confounding by insulin use, we ran an
analysis in which we directly compared
the risk of developing hypoglycemia in
current sulfonylurea users to the risk in
current metformin users in the absence of
any insulin exposure. Among patients
who did not use insulin, the adjusted
odds ratio for current use of a sulfonyl-
urea drug was 2.79 (95% CI 2.23–3.50)
compared with the reference group of
current metformin users (Table 4). We
further stratiﬁed this model by sex and
age (70 vs. 70 years); the adjusted
odds ratios for current sulfonylurea use
versus current metformin use (in the ab-
sence of insulin) for male and female
subjects were 2.42 (1.75–3.35) and
3.05 (2.21–4.21), respectively, and for
subjects aged 70 vs. 70 years were
2.71 (2.04–3.61) and 3.30 (2.18–5.00),
respectively.
We also intended to formally analyze
73 case subjects with severe hypoglyce-
mia and their 266 matched control sub-
jects, but the numbers were too small for
a meaningful model. Of 73 case subjects,
35 were on insulin (26 were on insulin
only and 9 used insulin in combination
with an oral antidiabetes drug), 22 used
sulfonylureas only, 3 metformin only,
11 a combination of sulfonylureas and
metformin, and 2 were past users of an-
tidiabetes drugs. Among 22 users of sul-
fonlyureas only, 16 used gliclazide, 5
glibenclamide, and 1 glimepiride, and 17
used a high dose and 5 a low dose.
CONCLUSIONS — Inourstudy,5of
50,048 type 2 diabetic patients (1 per
10,000subjects)developedlacticacidosis
while exposed to metformin, of whom
only 1 patient used metformin alone,
whereas 4 patients used metformin and
another oral antidiabetes agent concomi-
tantly. In only one patient on metformin,
noacutedeteriorationofamedicalcondi-
tion known to be a risk factor for lactic
acidosis could be identiﬁed. However, in
addition to hypertensive heart disease,
this patient suffered from liver cirrhosis,
which is associated with impaired clear-
ance of lactic acid and thereby predis-
poses to lactic acidosis. One case subject
was exposed to a sulfonylurea only. The
Table 3—Hypoglycemia risk by antidiabetes drug class and by duration of use among case (n  2,025) and control (n  7,278) subjects
Exposure Cases subjects Controls subjects
Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)* P value
Insulin (no use) 1,421 (70.2) 6,382 (87.7) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 86 (4.3) 87 (1.2) 4.54 (3.28–6.26) 6.26 (4.35–9.02) 0.0001
Current 5–14 Rx 107 (5.3) 154 (2.1) 2.20 (2.46–4.17) 5.46 (4.00–7.45) 0.0001
Current 15 Rx 325 (16.1) 352 (4.8) 4.46 (3.76–5.29) 7.56 (6.04–9.45) 0.0001
Sulfonylureas (no use) 312 (15.4) 2,162 (29.7) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 313 (15.5) 358 (4.9) 6.85 (5.54–8.47) 10.8 (8.48–13.8) 0.0001
Current 5–14 Rx 229 (11.3) 714 (9.8) 2.33 (1.91–2.85) 3.31 (2.64–4.14) 0.0001
Current 15 Rx 579 (28.6) 1,758 (24.2) 2.48 (2.11–2.91) 3.18 (2.64–3.84) 0.0001
Metformin (no use) 604 (29.8) 2,279 (31.3) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 150 (7.4) 397 (5.5) 1.49 (1.20–1.85) 2.32 (1.79–3.01) 0.0001
Current 5–14 Rx 242 (12.0) 877 (12.1) 1.12 (0.94–1.33) 1.74 (1.42–2.14) 0.0001
Current 15 Rx 534 (26.4) 1,889 (26.0) 1.19 (1.03–1.38) 1.36 (1.14–1.62) 0.001
Thiazolidinediones (no use) 1,827 (90.2) 6,743 (92.7) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 38 (1.9) 98 (1.4) 1.52 (1.03–2.34) 1.67 (1.08–2.59) 0.02
Current 5 Rx 83 (4.1) 239 (3.3) 1.41 (1.08–1.84) 1.44 (1.06–1.96) 0.02
Prandial glucose inhibitors (no use) 1,982 (97.9) 7,154 (98.3) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 5 (0.3) 11 (0.2) 1.69 (0.55–5.21) 3.01 (0.89–10.1) 0.08
Current 5 Rx 14 (0.7) 37 (0.5) 1.43 (0.76–2.70) 2.36 (1.13–4.92) 0.02
Acarbose (no use) 1,895 (93.6) 6,907 (94.9) 1.0 (reference) 1.0 (reference) —
Current 1–4 Rx 6 (0.3) 15 (0.2) 1.24 (0.47–3.28) 0.88 (0.30–2.62) 0.82
Current 5 Rx 24 (1.2) 84 (1.2) 0.99 (0.62–1.58) 0.90 (0.54–1.51) 0.70
Data are n (%), unless otherwise indicated. *Adjusted for each other, insulin, antihypertensive drugs, lipid-lowering agents, diuretics, inhaled and systemic
corticosteroids, anticonvulsants, antidepressants, neuroleptics, benzodiazepines, stomach acid–reducing drugs, and analgesics. Rx, prescription.
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ysis, but the crude incidence rates were
3.3 and 4.8 per 100,000 person-years for
current users of metformin or of sulfonyl-
ureas, respectively. Thus, there was no
greater risk of lactic acidosis among met-
formin users compared with users of
other oral antidiabetes drugs (3,17).
The term “metformin-associated lac-
tic acidosis” describes a temporal rela-
tionship of metformin use and the occur-
rence of lactic acidosis. Sometimes, this
term is used to suggest causality, which
couldonlybeprovenbyapositiverechal-
lenge and elimination of contributing
factors. The vast majority of metformin-
associated lactic acidosis cases in the
literature describe patients who had pre-
disposing medical conditions, such as
acute heart failure, hypovolemia due to
abdominal infection or bleeding, sepsis,
exacerbated chronic obstructive pulmo-
narydisease,orlivercirrhosis(2,18).Nu-
merous case reports have associated
metformin with lactic acidosis in patients
with acute renal failure or severely im-
paired renal function (19). However, no
correlation between lactate serum con-
centrations, metformin serum concentra-
tions, and mortality have been reported
(6,19). Although debated (2,20), im-
pairedrenalfunctionisconsideredtobea
risk factor for the development of met-
formin-associated lactic acidosis. Inter-
estingly, similar incidence rates for lactic
acidosis with or without metformin use
have been reported in diabetic patients
(3,5). These ﬁndings suggest that diabe-
tes,ratherthanmetformin,maybealead-
ing risk factor for lactic acidosis.
In our study population, 2,025 of
50,048(4.1%)patientsexperiencedaﬁrst
episodeofhypoglycemiaundertreatment
withoralantidiabetesdrugs.Asexpected,
useofinsulinwasanimportantriskfactor
for hypoglycemia, as was use of sulfonyl-
ureas (adjusted odds ratio 3.73). In con-
trast, metformin (odds ratio 1.42) was
associated with only a small relative risk
elevation, as reported previously (1,9).
The proportion of patients developing
documented hypoglycemia in our study
population was similar to previous stud-
ies (9,11), although reported frequencies
varied substantially (0–73,000 per
100,000 person-years) (7,11,21). In our
study, hypoglycemia had to be severe
enough to lead to a GP or hospital visit,
while minor events may have been
missed. Thus, our ﬁndings may be based
on hypoglycemic episodes of moderate to
high severity; randomized trials with pre-
speciﬁed protocols and intensive fol-
low-up may produce higher absolute
risks for hypoglycemic events.
In our study population, renal failure
was an independent risk factor for hypo-
glycemia,whileobesity(BMI30kg/m
2)
was inversely related with the risk of de-
veloping hypoglycemia, probably due to
increased insulin resistance and poorer
diabetes control in obese patients. As pre-
viously observed (22), sex did not predis-
pose to hypoglycemia. Interestingly,
current smokers had a decreased risk of
hypoglycemia compared with nonsmok-
ers in our study. These results differ from
the ﬁndings of a recent study in type 1
diabetic subjects that reported a higher
risk of hypoglycemia in smokers (23).
Particularly for sulfonylurea users, the
risk of developing hypoglycemia was
substantially higher in the early phase of
therapy. Similar ﬁndings were reported
before, with elevated risk for incidental
sulfonylurea use compared with continu-
ous use (11). Possible explanations in-
clude worsening of glycemic control over
time,betterpatienteducationtoavoidhy-
poglycemia over time, or reduced aware-
ness of hypoglycemia in long-standing
diabetes.
Long-acting sulfonylureas were asso-
ciated with a higher risk of hypoglycemic
episodes than short-acting sulfonylureas
(7,11).Inourstudy,theoddsratiosforall
hypoglycemic events were closely similar
for most sulfonylureas (data not shown).
Among the 19 case subjects with severe
hypoglycemia who used a sulfonylurea
drug, gliclazide was highly represented,
with 16 case subjects, while 5 patients
used glibenclamide. We were not able to
conduct formal multivariate comparisons
of the hypoglycemia risk during current
use of these drugs because of the small
number of case subjects.
In conclusion, we identiﬁed seven
cases of lactic acidosis, among whom ﬁve
subjects were current users of metformin.
In these ﬁve case subjects, chronic dis-
eases and an acute deterioration of the
clinical situation preceded lactic acidosis.
This supports the previous notion that
metformin-associated lactic acidosis is
rareandisobservedinassociationwithan
acutely worsening clinical condition. The
risk for moderate to severe hypoglycemia
was approximately threefold for users of
sulfonylureas, particularly in the early
phase of therapy, compared with met-
formin users. Considering morbidity of
severehypoglycemiaandthelowabsolute
risk of lactic acidosis associated with met-
formin use, clinicians must carefully en-
sure that risks outweigh beneﬁts when
withholding metformin from patients
with type 2 diabetes.
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Table 4—Hypoglycemia risk by current exposure to sulfonylurea drugs, metformin, and/or insulin among case (n  2,025) and control (n 
7,278) subjects
Exposure to antidiabetes drugs
Cases subjects Control subjects
Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)* P value Sulfonylurea Metformin Insulin
Current No No 392 (19.4) 1,213 (16.7) 2.86 (2.31–3.55) 2.79 (2.23–3.50) 0.0001
No Current No 151 (7.5) 1,383 (19.0) 1.0 (reference) 1.0 (reference) —
No No Current 7 (0.4) 4 (0.1) 14.9 (4.1–54.5) 16.5 (4.2–65.0) 0.0001
Current Current No 526 (26.0) 1,194 (16.4) 4.07 (3.33–4.98) 4.04 (3.27–4.98) 0.0001
Current No Current 17 (0.8) 3 (0.04) 50.5 (14.4–176) 39.9 (11.2–142) 0.0001
No Current Current 53 (2.6) 54 (0.7) 8.72 (5.63–13.5) 8.73 (5.49–13.9) 0.0001
Current Current Current 19 (0.9) 22 (0.3) 8.61 (4.47–16.6) 8.86 (4.47–17.6) 0.0001
Dataaren(%)unlessotherwiseindicated.*Adjustedforuseofotheroralantidiabetesdrugs,insulin,antihypertensivedrugs,lipid-loweringagents,diuretics,inhaled
and systemic corticosteroids, anticonvulsants, antidepressants, neuroleptics, benzodiazepines, stomach acid–reducing drugs, and analgesics.
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